

For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.

Ivermectin and Pyrantel Tablets **WRIGGLE-S™** Yum-Tab!

COMPOSITION:
Each uncoated tablet contains:
Ivermectin BP 68 mcg
Pyrantel Pamoate USP
equivalent to Pyrantel 57 mg

Ivermectin and Pyrantel Tablets **WRIGGLE-M™** Yum-Tab!

COMPOSITION:
Each uncoated tablet contains:
Ivermectin BP 136 mcg
Pyrantel Pamoate USP
equivalent to Pyrantel 114 mg

Ivermectin and Pyrantel Tablets **WRIGGLE-L™** Yum-Tab!

COMPOSITION:
Each uncoated tablet contains:
Ivermectin BP 272 mcg
Pyrantel Pamoate USP
equivalent to Pyrantel 227 mg

Administer once a month to prevent heartworm disease and to treat and control ascarid and hookworm infections in dogs.

DESCRIPTION:

WRIGGLE Tablet is a combination of two anthelmintics used to prevent canine heartworm disease and for the treatment and control of ascarids and hookworms.

INDICATIONS:

For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (*Dirofilaria immitis*) for a month (30 days) after infection and for the treatment and control of ascarids (*Toxocara canis*, *Toxascaris leonina*) and hookworms (*Ancylostoma caninum*, *Uncinaria stenocephala*, *Ancylostoma braziliense*).

DOSAGE AND ADMINISTRATION:

Dosage:
WRIGGLE Tablet should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) of body weight.

The recommended dosing schedule for prevention of canine heartworm disease and for the treatment and control of ascarids and hookworms is as follows:

Dog Weight	Tablet per month	Ivermectin Content	Pyrantel Content
Up to 25 lb	1	68 mcg	57 mg
26 to 50 lb	1	136 mcg	114 mg
51 to 100 lb	1	272 mcg	227 mg

WRIGGLE Tablet is recommended for dogs 6 weeks of age and older. For dogs over 100 lb use the appropriate combination Or as directed by the Veterinarian.

Administration:

Oral

As most dogs find WRIGGLE Tablet palatable, the product can be offered to the dog by hand. Alternatively, it may be added intact to a small amount of dog food. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

Ivermectin and Pyrantel Tablet should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog's last exposure to mosquitoes. When replacing another heartworm preventive product in a heartworm disease preventive program, the first dose of Ivermectin and Pyrantel Tablet must be given within a month (30 days) of the last dose of the former medication. If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be reduced. Therefore, for optimal performance, the chewable must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with Ivermectin and Pyrantel Tablet and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms. Monthly treatment with Ivermectin and Pyrantel Tablet also provides effective treatment and control of ascarids (*T. canis*, *T. leonina*) and hookworms (*A. caninum*, *U. stenocephala*, *A. braziliense*). Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.

EFFICACY:

The recommended dose and regimen, are effective against the tissue larval stage of *D. immitis* for a month (30 days) after infection and, as a result, prevent the development of the adult stage. Ivermectin and Pyrantel Tablet is also effective against canine ascarids (*T. canis*, *T. leonina*) and hookworms (*A. caninum*, *U. stenocephala*, *A. braziliense*).

TARGET SPECIES:

Dogs

PHARMACODYNAMIC PROPERTIES:

Pharmacotherapeutic group: Anthelmintics, Ivermectin, combinations.
ATCvet code: QP 54AA51

PHARMACODYNAMICS:

Ivermectin is a macrocyclic-lactone derivative which has a broad antiparasitic activity against nematodes and arthropods. It acts by inhibiting nerve impulses. Its mode of action includes the glutamate-gated chloride ion channels. Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarisation of the nerve or muscle cell, resulting in paralysis and death of the relevant parasites..

Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis of the nematodes and thereby allow removal from the gastro intestinal (GI) system by peristalsis.

PHARMACOKINETICS:

After oral administration at the recommended dosage, the Ivermectin peak plasma concentration of around 12 ng/mL (C_{max}) was reached between 4 and 8 hours (T_{max}). The oral mean absolute bioavailability of Ivermectin is around 9%. Ivermectin is a poorly metabolised compound. Due to its lipophilic nature, ivermectin is excreted in bile and ultimately eliminated from the body via the faeces. In horses, about 75% of the administered dose is excreted via the faeces after an oral administration of ivermectin at the recommended dose. Moreover 90% of the total drug is excreted within 4 days post-administration. Approximately 2% of unchanged ivermectin and metabolites are excreted in urine.

The pamoate salt of pyrantel has low aqueous solubility, an attribute that reduces absorption from the gut and allows the drug to reach and be effective against parasites in the large intestine. Following absorption, Pyrantel is quickly and almost completely metabolized into inactive metabolites that are excreted rapidly in the urine.

WARNING & PRECAUTION:

- Do not exceed the recommended dosage.
- All dogs should be tested for existing heartworm infection before starting treatment with Ivermectin and Pyrantel Tablet which is not effective against adult *D. immitis*. Infected dogs must be treated to remove adult heartworms and microfilariae before initiating a program with Ivermectin and Pyrantel Tablet.
- In case of accidental ingestion by humans, seek medical advice immediately and show the package leaflet or the label to the physician.

CONTRAINDICATIONS:

Do not administer to animals other than those for which it is indicated.

Hypersensitivity to any of the Ingredients.

ADVERSE EFFECTS:

Vomiting or diarrhoea within 24 hours of dosing was rarely observed (1.1% of administered doses). Depression/lethargy, vomiting, anorexia, diarrhoea, mydriasis, ataxia, staggering, convulsions and hypersalivation have been reported following the use of Ivermectin and Pyrantel Tablet.

SAFETY:

Ivermectin and Pyrantel Tablet has shown a wide margin of safety at the recommended dose level in dogs, including pregnant or breeding bitches, stud dogs and puppies aged 6 or more weeks.

OVERDOSE:

Ivermectin and Pyrantel Tablet are well tolerated in dogs.

STORAGE:

Store below 30°C. Protect from light.

PRESENTATION:

1 Blister containing 6 Tablets is packed in a Carton along with the Pack Insert.

**VETERINARY.
FOR ANIMAL TREATMENT ONLY.
NOT FOR HUMAN USE.**

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

Veko
A VETCO GROUP COMPANY

Manufactured & Marketed by:
Veko Care Pvt. Ltd.
Plot No. E-48 & 49, MIDC, Ranjangaon, Dist-Pune.
Maharashtra, India. Pin Code: 412220
Customer care: care@vekocare.com
TM : Trademark of Veko Care

VPP-TE067